• SPX
  • $5,948.71
  • 0.53 %
  • $31.60
  • DJI
  • $43,870.35
  • 1.06 %
  • $461.88
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,184.05
  • 0.43 %
  • $34.78
  • IXIC
  • $18,972.42
  • 0.03 %
  • $6.28
Janux Therapeutics, Inc. (JANX) Stock Price, News & Analysis

Janux Therapeutics, Inc. (JANX) Stock Price, News & Analysis

Currency in USD Disclaimer

$46.57

-$2.39

(-4.88%)

Day's range
$45.95
Day's range
$49.78
50-day range
$42.54
Day's range
$58.06
  • Country: US
  • ISIN: US47103J1051
52 wk range
$7.79
Day's range
$65.6
  • CEO: Dr. David Alan Campbell Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 37.92
  • Piotroski Score 3.00
  • Grade Overweight
  • Symbol (JANX)
  • Company Janux Therapeutics, Inc.
  • Price $46.57
  • Changes Percentage (-4.88%)
  • Change -$2.39
  • Day Low $45.95
  • Day High $49.78
  • Year High $65.60

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 03/07/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $63.00
  • High Stock Price Target $70.00
  • Low Stock Price Target $42.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$1.20
  • Trailing P/E Ratio -36.8
  • Forward P/E Ratio -36.8
  • P/E Growth -36.8
  • Net Income $-58,293,000

Income Statement

Quarterly

Annual

Latest News of JANX

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Janux Therapeutics, Inc. Frequently Asked Questions

  • What is the Janux Therapeutics, Inc. stock price today?

    Today's price of Janux Therapeutics, Inc. is $46.57 — it has decreased by -4.88% in the past 24 hours. Watch Janux Therapeutics, Inc. stock price performance more closely on the chart.

  • Does Janux Therapeutics, Inc. release reports?

    Yes, you can track Janux Therapeutics, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Janux Therapeutics, Inc. stock forecast?

    Watch the Janux Therapeutics, Inc. chart and read a more detailed Janux Therapeutics, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Janux Therapeutics, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Janux Therapeutics, Inc. stock ticker.

  • How to buy Janux Therapeutics, Inc. stocks?

    Like other stocks, JANX shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Janux Therapeutics, Inc.'s EBITDA?

    Janux Therapeutics, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Janux Therapeutics, Inc.’s financial statements.

  • What is the Janux Therapeutics, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -7.2118025486, which equates to approximately -721.18%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Janux Therapeutics, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Janux Therapeutics, Inc.'s financials relevant news, and technical analysis. Janux Therapeutics, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Janux Therapeutics, Inc. stock currently indicates a “sell” signal. For more insights, review Janux Therapeutics, Inc.’s technical analysis.

  • A revenue figure for Janux Therapeutics, Inc. for its last quarter?

    Janux Therapeutics, Inc. published it's last quarterly revenues at $439,000.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.